Alkem reports 11percent revenue growth, 22percent rise in net profit in Q1 FY26

Mumbai, August 12th, 2025: Alkem Laboratories Ltd. today announced its standalone and consolidated financial results for the first quarter ended June 30, 2025. The Board of Directors took record of these results at its meeting held in Mumbai today.

Key Financial Metrics

Key highlights of Q1 FY26 financial performance

• Total Revenue from Operations was ₹33,711 million, with YoY growth of 11.2%.

• India sales were ₹22,650 million, YoY growth of 12.0%.
• International sales were ₹10,539 million, with YoY growth of 8.9%.

• Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were ₹7,391 million, resulting in an EBITDA margin of 21.9% vs. 20.1% in Q1 FY25. EBITDA grew by 21.4% YoY.

• R&D expenses for Q1 FY26 were ₹1,184 million, or 3.5% of total revenue from operations, vs. ₹1,257 million in Q1 FY25 at 4.1% of total revenue from operations.

• Profit before tax before exceptional items was ₹7,581 million, YoY growth of 22.4%.

• Net Profit (after Minority Interest) was ₹6,643 million, YoY growth of 21.8%.

• According to IQVIA (SSA) data, for Q1 FY26:

• The Company registered a growth of 9.7% YoY compared to the Indian Pharmaceutical Market (IPM), which grew by 8.5%.
• We achieved strong overall volume growth of 2.9%, outperforming the IPM volume growth of 1.5% by 140 basis points.

Commenting on the Q1 FY26 results, Dr. Vikas Gupta, CEO of Alkem, said, “Q1 FY26 marked a strong start to the year, with healthy growth across both our domestic and international markets. Our performance was driven by strong topline growth and an improved gross margin, which resulted in a better EBITDA profile. These results reflect the disciplined execution of our strategy, focused investments, and a deliberate pivot toward value-accretive products and markets with a sharper focus on EBITDA. We are strategically accelerating our focus on the non-US business segment by strengthening our presence in high-potential non-US markets and capturing new opportunities that align with our long-term growth ambitions.”

Operational Highlights

Domestic Business – Q1 FY26 Key Highlights

• India sales were ₹22,650 million, YoY growth of 12.0%.
• The contribution of domestic sales to total sales in Q1 FY26 was 68.3% vs. 67.6% in Q1 FY25.
• As per IQVIA (SSA) data, during the quarter, we have outperformed IPM in seven therapies: Gastrointestinal grew by ~1.6X, VMN ~2.3X, Pain ~1.4X, Anti-Diabetics ~1.4X, Neuro/CNS ~1.2X, Respiratory ~1.4X, and Derma ~1.1X.

International Business – Q1 FY26 Key Highlights

• International sales were ₹10,539 million, YoY growth of 8.9%.
• US sales were ₹6,982 million, YoY growth of 8.8%.
• US business sales contributed 21.0% to total sales in Q1 FY26.
• Non-US sales were ₹3,556 million, YoY growth of 9.1%.
• Non-US business sales contributed 10.7% to total sales in Q1 FY26.
• During the Q1 FY26, for the US market, the Company filed its first BLA, received 05 ANDA approvals (including 02 tentative approvals) and launched 03 products.
• As of June 30, 2025, the Company had filed 185 ANDAs, 02 NDAs and 01 BLA with the USFDA. It has received approvals for 160 ANDAs (including 15 tentative approvals) and 02 NDAs.